TrialA Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Trial details
- Registry ID
- NCT03796962
- Phase
- Phase 2
XENE
Xenon Pharmaceuticals Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
13Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceXEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Trial details
- Registry ID
- NCT04639310
- Phase
- Phase 3
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Trial details
- Registry ID
- NCT04912856
- Phase
- Phase 3
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
Trial details
- Registry ID
- NCT05376150
- Phase
- Phase 2
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Trial details
- Registry ID
- NCT05614063
- Phase
- Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Trial details
- Registry ID
- NCT05667142
- Phase
- Phase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Trial details
- Registry ID
- NCT05716100
- Phase
- Phase 3
An Open-label Study of XEN1101 in Epilepsy
Trial details
- Registry ID
- NCT05718817
- Phase
- Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Trial details
- Registry ID
- NCT06775379
- Phase
- Phase 3
An Open-Label Study of Azetukalner in Major Depressive Disorder
Trial details
- Registry ID
- NCT06922110
- Phase
- Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Trial details
- Registry ID
- NCT07076407
- Phase
- Phase 3
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Trial details
- Registry ID
- NCT07172516
- Phase
- Phase 3
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Trial details
- Registry ID
- NCT07217860
- Phase
- Phase 3
Latest recorded trial changes
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150 · Xenon Pharmaceuticals Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score.
Measure: Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.
+ After
Measure: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
An Open-label Study of XEN1101 in Epilepsy
NCT05718817 · Xenon Pharmaceuticals Inc.
Primary completion date changed
− Before
Jul 2028
+ After
Apr 2033
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063 · Xenon Pharmaceuticals Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
360 participants (planned)
+ After
380 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Dec 2025
+ After
12 Jan 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100 · Xenon Pharmaceuticals Inc.
Primary completion date changed
− Before
Aug 2025
+ After
Oct 2026